Department of Medicine, Division of Hematology Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
Vanderbilt University Medical School, Nashville, TN, USA.
Curr Oncol Rep. 2024 Nov;26(11):1469-1488. doi: 10.1007/s11912-024-01607-5. Epub 2024 Oct 23.
This review highlights advances and recent changes in the treatment paradigm for advanced esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma (GEJAC).
Chemotherapy remains the backbone of treatment for advanced EAC/GEJAC. New targets/agents include immunotherapy, HER-2, claudin18.2, and FGFR2b, with various mechanisms (CAR-T, bispecific mAB, ADCs) altering the treatment landscape against these targets. The approaches to these targets may act together, in sequence, and even synergistically to improve outcomes. Herein, we review the state of the field, including highlighting ongoing clinical trials and additional emerging agents and approaches.
本文重点介绍了晚期食管腺癌（EAC）和胃食管交界处腺癌（GEJAC）治疗模式的进展和最新变化。
化疗仍然是晚期 EAC/GEJAC 的治疗基础。新的靶点/药物包括免疫疗法、HER-2、claudin18.2 和 FGFR2b，各种机制（CAR-T、双特异性 mAB、ADC）改变了针对这些靶点的治疗格局。这些靶点的治疗方法可以联合、序贯甚至协同作用，以改善疗效。本文综述了该领域的现状，包括正在进行的临床试验以及其他新的药物和方法。
Zotero 插件